Additional Proxy Soliciting Materials (definitive) (defa14a)
August 04 2015 - 6:35AM
Edgar (US Regulatory)
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the Securities
Exchange Act of 1934
Filed by the Registrant x
Filed by a Party other than the Registrant
¨
Check the appropriate box:
¨ |
Preliminary Proxy Statement |
¨ |
Confidential, for the use of the Commission only (as permitted by Rule 14a-6(e)(2)) |
¨ |
Definitive Proxy Statement |
x |
Definitive Additional Materials |
¨ |
Soliciting Material Pursuant to §240.14a-12 |
Amarantus BioScience Holdings, Inc. |
(Name of Registrant as Specified In Its Charter) |
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) |
Payment of Filing Fee (Check the appropriate box):
x |
No fee required. |
¨ |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
Title of each class of securities to which transaction applies: |
|
(2) |
Aggregate number of securities to which transaction applies: |
|
(3) |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
|
(4) |
Proposed maximum aggregate value of transaction: |
|
(5) |
Total fee paid: |
¨ |
Fee paid previously with preliminary materials. |
¨ |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-1l (a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|
(1) |
Amount Previously Paid: |
|
(2) |
Form, Schedule or Registration Statement No.: |
|
(3) |
Filing Party: |
|
(4) |
Date Filed: |
AMARANTUS ANNOUNCES ADJOURNMENT OF ANNUAL
MEETING
SAN FRANCISCO, CA, and GENEVA, SWITZERLAND –
August 3, 2015 – Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), a
biotechnology company developing therapeutic and diagnostic product candidates in orphan indications and neurology, announced
that its 2015 Annual Meeting of Stockholders scheduled for, and convened on August 3, 2015, was adjourned due to the lack of
requisite quorum. Only stockholders of record on the record date July 10, 2015 are entitled to and are being requested to
vote. The annual meeting has been adjourned to August 7, 2015 at 10:00 a.m. EDT at Sichenzia Ross Friedman Ference LLP, 61
Broadway, 32nd Floor, New York, New York 10006 to allow additional time for the stockholders to vote on the
proposals set forth in the Company's proxy statement filed with the Securities and Exchange Commission (“SEC”),
which is available at http://www.sec.gov/Archives/edgar/data/1424812/000114420415043459/v415847_def14a.htm.
During the period of the adjournment, the Company will continue
to solicit proxies from its stockholders with respect to the proposals set forth in the Company's proxy statement. Proxies previously
submitted in respect of the meeting will be voted at the adjourned meeting unless properly revoked.
The Company encourages all stockholders who have not yet voted
to do so before August 6, 2015 at 11.59 p.m. EDT. The beneficial stockholders may vote by internet at www.proxyvote.com, or by
telephone at 800-454-8683. Record holders may return a properly executed proxy card to18 Lafayette Place, Woodmere, NY 11598 or
they may vote by internet at www.vstocktransfer.com/proxy. No changes have been made in the proposals to be voted on by stockholders
at the annual meeting. The Company's proxy statement and any other materials filed by the Company with the SEC remain unchanged
and can be obtained free of charge at the SEC's website at www.sec.gov.
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (OTCQX: AMBS) is a biotechnology
company developing treatments and diagnostics for diseases in the areas of neurology and orphan diseases. AMBS’ Therapeutics
division has development rights to eltoprazine, a small molecule currently in a Phase 2b clinical program for Parkinson's disease
levodopa-induced dyskinesia with the potential to expand into adult ADHD and Alzheimer’s aggression. The Company has an exclusive
worldwide license to intellectual property rights associated to Engineered Skin Substitute (ESS), an orphan drug designated autologous
full thickness skin replacement product in development for the treatment of severe burns currently preparing to enter Phase 2 clinical
studies. AMBS owns the intellectual property rights to a therapeutic protein known as mesencephalic-astrocyte-derived neurotrophic
factor (MANF) and is developing MANF as a treatment for orphan ophthalmic disorders, initially in retinitis pigmentosa (RP). AMBS
also owns the discovery of neurotrophic factors (PhenoGuard™) that led to MANF’s discovery.
AMBS’ Diagnostics division owns the rights to MSPrecise®,
a proprietary next-generation DNA sequencing (NGS) assay for the identification of patients with relapsing-remitting multiple
sclerosis (RRMS), and has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for
Alzheimer's disease, which was developed by Prof. Thomas Arendt, Ph.D., from the University of Leipzig, and owns further intellectual
property for the diagnosis of Parkinson's disease (NuroPro®). For further information please visit www.Amarantus.com,
or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
Forward-Looking Statements
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are forward-looking statements. These forward-looking statements generally are
identified by the words "believes," "project," "expects," "anticipates," "estimates,"
"intends," "strategy," "plan," "may," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions. Forward-looking statements are based on current
expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from
the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include,
but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates,
competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating
forward-looking statements and undue reliance should not be placed on such statements.
Investor and Media Contact:
Jenene Thomas
Jenene Thomas Communications, LLC
Investor Relations and Corporate Communications Advisor
T: (US) 908.938.1475
E: jenene@jenenethomascommunications.com
Source: Amarantus Bioscience Holdings, Inc.
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2023 to Apr 2024